Sona Narula
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sona Narula has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Brenda Banwell
Perelman School of Medicine at the University of Pennsylvania, Children's Hospital of Philadelphia, Division of Neurology, Philadelphia, PA 19104, United States
3 shared publicationsAmy T. Waldman
The Children’s Hospital of Philadelphia
2 shared publicationsAngela J. Waanders
1 shared publicationBrook Hill
1 shared publication- Chelsea Kotch
Department of Pediatrics, University of Pennsylvania Perelman School of Medicine , Philadelphia, Pennsylvania
1 shared publication Christopher Perrone
1 shared publication
Latest Publications
- Open Access
- 1 November 2019
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 6 (6)
Expanding the MOG phenotype
- 1 November 2019
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 6 (6)
Open AccessExpanding the MOG phenotype
- 10 November 2017
- Published by Springer Nature
- p. 189-194
Neuromyelitis Optica Spectrum Disorder with Brainstem Presentation
- 10 November 2017
- Published by Springer Nature
- p. 189-194
Neuromyelitis Optica Spectrum Disorder with Brainstem Presentation
- 22 November 2016
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 6 (sup6) , 3-7
Pediatric Multiple Sclerosis: Updates in epidemiology, Clinical Features and Management
Consensus definitions for acute demyelinating syndromes in children have led to increased recognition of pediatric multiple sclerosis and improved our understanding of its pathogenesis, epidemiology and treatment. An estimated 2–10% of MS patients experience their first clinical symptom in childhood. Multiple genetic and environmental risk factors have been identified in the pathogenesis of pediatric MS, although further research to determine their interplay is required. Clinical trials of emerging disease-modifying therapies in children are nearing completion. Additional treatment options are expected to bring associated challenges. As pediatric MS remains relatively uncommon overall, international collaboration is essential to facilitate research.
- 22 November 2016
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 6 (sup6) , 3-7
Pediatric Multiple Sclerosis: Updates in epidemiology, Clinical Features and Management
Consensus definitions for acute demyelinating syndromes in children have led to increased recognition of pediatric multiple sclerosis and improved our understanding of its pathogenesis, epidemiology and treatment. An estimated 2–10% of MS patients experience their first clinical symptom in childhood. Multiple genetic and environmental risk factors have been identified in the pathogenesis of pediatric MS, although further research to determine their interplay is required. Clinical trials of emerging disease-modifying therapies in children are nearing completion. Additional treatment options are expected to bring associated challenges. As pediatric MS remains relatively uncommon overall, international collaboration is essential to facilitate research.
- 1 February 2016
- Published by Elsevier in Current Problems in Pediatric and Adolescent Health Care
- Vol. 46 (2) , 62-69
New Perspectives in Pediatric Neurology—Multiple Sclerosis
- 1 February 2016
- Published by Elsevier in Current Problems in Pediatric and Adolescent Health Care
- Vol. 46 (2) , 62-69
New Perspectives in Pediatric Neurology—Multiple Sclerosis
- 1 April 2015
- Published by Elsevier in La Presse Médicale
- Vol. 44 (4) , e153-e158
Treatment of multiple sclerosis in children and its challenges
- 1 April 2015
- Published by Elsevier in La Presse Médicale
- Vol. 44 (4) , e153-e158
Treatment of multiple sclerosis in children and its challenges
- 1 April 2015
- Published by Elsevier in Pediatric Neurology
- Vol. 52 (4) , 446-449
Elevated Cerebrospinal Fluid Opening Pressure in a Pediatric Demyelinating Disease Cohort
- 1 April 2015
- Published by Elsevier in Pediatric Neurology
- Vol. 52 (4) , 446-449
Elevated Cerebrospinal Fluid Opening Pressure in a Pediatric Demyelinating Disease Cohort
- 15 February 2015
- Published by Springer Nature in Current Treatment Options in Neurology
- Vol. 17 (3) , 1-12
Treatment of Pediatric Multiple Sclerosis
The past 10 years have borne witness to increased recognition and diagnosis of pediatric multiple sclerosis (MS). Additionally, during this time period, the number of treatment options available for MS patients has increased significantly, as has the number of studies evaluating the use of these therapies in children. Though the U.S. Food and Drug Administration has not formally approved any of these therapies for use in pediatric MS, a number of injectable, oral, and intravenous treatments are currently being used off-label in these children. Disease modifying therapy should be initiated promptly following a diagnosis of MS. The patient and family should be engaged in the choice of therapy as this is likely to promote adherence. First-line options include any of the injectable therapies (glatiramer acetate, interferon beta), which have roughly similar efficacy (approximately 30 % reduction of clinical relapses). If a patient has breakthrough disease or persistent, unmanageable side effects, transition to a different first-line therapy or escalation to a second-line therapy, such as natalizumab, should be considered. Though the efficacy of second-line agents is higher, the potential risk of serious adverse effects also increases. New therapies, including oral agents, are now being rigorously studied with pediatric clinical trials and may provide safe alternatives for patients that are either unresponsive or intolerant to currently available medications. When necessary, acute exacerbations can be treated with corticosteroids. Intravenous methylprednisolone at a dosage of 30 mg/kg/day (maximum dose 1000 mg/day) for 3–5 days is recommended with severe attacks. If patients are unresponsive to corticosteroids, treatment with either intravenous immunoglobulin or plasma exchange may be required. Fatigue, spasticity, and pain can also occur in pediatric patients with MS. Medications are needed if symptoms are severe and impact quality of life.
- 15 February 2015
- Published by Springer Nature in Current Treatment Options in Neurology
- Vol. 17 (3) , 1-12
Treatment of Pediatric Multiple Sclerosis
The past 10 years have borne witness to increased recognition and diagnosis of pediatric multiple sclerosis (MS). Additionally, during this time period, the number of treatment options available for MS patients has increased significantly, as has the number of studies evaluating the use of these therapies in children. Though the U.S. Food and Drug Administration has not formally approved any of these therapies for use in pediatric MS, a number of injectable, oral, and intravenous treatments are currently being used off-label in these children. Disease modifying therapy should be initiated promptly following a diagnosis of MS. The patient and family should be engaged in the choice of therapy as this is likely to promote adherence. First-line options include any of the injectable therapies (glatiramer acetate, interferon beta), which have roughly similar efficacy (approximately 30 % reduction of clinical relapses). If a patient has breakthrough disease or persistent, unmanageable side effects, transition to a different first-line therapy or escalation to a second-line therapy, such as natalizumab, should be considered. Though the efficacy of second-line agents is higher, the potential risk of serious adverse effects also increases. New therapies, including oral agents, are now being rigorously studied with pediatric clinical trials and may provide safe alternatives for patients that are either unresponsive or intolerant to currently available medications. When necessary, acute exacerbations can be treated with corticosteroids. Intravenous methylprednisolone at a dosage of 30 mg/kg/day (maximum dose 1000 mg/day) for 3–5 days is recommended with severe attacks. If patients are unresponsive to corticosteroids, treatment with either intravenous immunoglobulin or plasma exchange may be required. Fatigue, spasticity, and pain can also occur in pediatric patients with MS. Medications are needed if symptoms are severe and impact quality of life.